Capital Cube • 8 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Investor's Business Daily • 9 days ago
Biotech stocks will likely close 2016 down by double digits, but 2017 is filled with catalysts, RBC analyst Adnan Butt says.
Insider Monkey • 9 days ago
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]
Barrons.com • 9 days ago
Biotech investors Felix and Julian Baker paid more than $150 million to increase their holdings in three companies in November. The purchases are impressively bullish as the Bakers are already the largest beneficial holders of Seattle Genetics (SGEN), BeiGene (BGNE) and Invitae (NVTA). Entities controlled by the Bakers bought 1,611,562 shares of Seattle Genetics for $91.8 million, about $56.93 a share, from Nov. 1 through 8 on the open market, regulatory filings show.
Barrons.com • 25 days ago
Credit Suisse Our small- to midcap biotech coverage universe ended the week up 29%, but remains down 14% year-to-date. The biotech sector rallied this past week on the back of Donald Trump’s Presidential ...
Investor's Business Daily • 26 days ago
Donald Trump will likely seek faster drug pipelines, buoying Medidata Solutions, KeyBanc analyst Donald Hooker said Monday.
Insider Monkey • 26 days agoIncyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks
Baker Bros. Advisors is a fund managed by Julian Baker and Felix Baker that mainly invests in biotechnology companies, and today we are going to take a closer look at four of its favorite health picks, including Incyte Corporation (NASDAQ:INCY), Seattle Genetics, Inc. (NASDAQ:SGEN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). At the end of […]
24/7 Wall St. • 27 days agoMassive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics and More
After a dramatic conclusion to the presidential race, insider buying was dramatically larger than we have seen in months, and it could continue the rest of the year.
American City Business Journals • 29 days ago
Seattle Genetics will be ready to seek Food and Drug Administration approval for its most important and potentially most lucrative drug sooner than expected, its top executive said. Seattle Genetics has been testing its flagship Adcetris drug as a first line of treatment for patients with advanced lymphoma instead of as a last resort for the cancer, which is currently the drug's only FDA-approved application. CEO Clay Siegall said he expects final results from the Echelon-1 trial in 2017, rather than as late as mid 2018.
SGEN : Summary for Seattle Genetics, Inc. - Yahoo Finance
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||63.90 x 1500|
|Ask||67.86 x 100|
|Day's Range||64.81 - 68.68|
|52 Week Range||26.02 - 75.36|
|PE Ratio (TTM)||-82.85|
|Earnings Date||Feb 7, 2017 - Feb 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||56.43|